Lixazinone (RS-82856) is a selective inhibitor of cGMP-inhibited phosphodiesterase ( PDE3 ) with an IC 50 value of 22 nM. Lixazinone exhibits positive inotropic effects, afterload reduction and antithrombotic properties. Lixazinone increases cyclic adenosine monophosphate (cAMP) levels in human platelets, inhibits thrombin-induced aggregation of human platelets, and blocks the photolabeling of PDE3 active sites by [ 32 P]cGMP. Lixazinone can be used in the research of polycystic kidney disease and congestive heart failure.
Products | Products > Disease Areas > Polycystic Kidney Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Heart Disease | Products > Disease Areas > Renal Disease | Products > Disease Areas > Heart Failure | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Endocrinology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Phosphodiesterase (PDE)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.